Continuum Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Continuum Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.98M	Sell	104,492 -44	-0%	-$2.41K	0.48%	40
2026 Q1	$5.91M	Buy	104,536 +3,116	+3%	+$182K	0.57%	36
2025 Q4	$6.03M	Buy	+101,420	New	+$5.52M	0.6%	41
2025 Q2	–	Sell	-11	Closed	-$778	–	547
2025 Q1	$778	Sell	11 -6	-35%	-$404	﹤0.01%	1542
2024 Q4	$1.12K	Sell	17 -10	-37%	-$670	﹤0.01%	1589
2024 Q3	$1.77K	Sell	27 -8	-23%	-$669	﹤0.01%	1480
2024 Q2	$2.88K	Hold	35	–	–	﹤0.01%	1211
2024 Q1	$2.86K	Buy	+35	New	+$3.13K	﹤0.01%	1199

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Continuum Advisory's BMRN Position: Q2 2026 in Review

Continuum Advisory reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.04% in Q2 2026, selling an estimated $2.41K and leaving 104,492 shares worth $5.98M. The position accounts for 0.48% of the portfolio, ranked #40.

Continuum Advisory first reported a position in BMRN in Q1 2024 and has held it in 8 quarters since. The position peaked at $6.03M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Continuum Advisory held 104,492 shares of BioMarin Pharmaceuticals worth $5.98M as of Q2 2026.
Continuum Advisory sold 44 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.41K.
BioMarin Pharmaceuticals made up 0.48% of Continuum Advisory's portfolio in Q2 2026, its #40 holding.
Continuum Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Continuum Advisory's BioMarin Pharmaceuticals position peaked at $6.03M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.